Skip to main content

Advertisement

Table 1 Baseline clinical and treatment characteristics of patients registered for prospective QoL assessment

From: Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases

age [years] median (range) 61 (33–84)
  total n = 151 100 %
primary tumor non-small cell lung cancer 70 46
small-cell lung cancer 20 13
melanoma 12 8
renal cell carcinoma 7 5
colorectal cancer 3 2
breast cancer 25 17
others 12 8
unknown 2 1
Karnofsky performance score ≥ 70 119 79
  < 70 30 20
  unknown 2 1
RPA classification 1 17 11
2 99 66
3 33 22
unknown 2 1
GPA classification 0-1.0 63 43
1.5-2.5 70 48
3.0 11 7
3.5-4.0 3 2
unknown 4 3
Barthel index 90-100 115 76
<90 34 23
unknown 2 1
fractionation of whole-brain radiotherapy 10x3 Gy 80 53
14x2.5 Gy 12 8
others 32 21
unknown 5 3
fractionation of stereotactic radiotherapy 1x18-20 Gy 10 7
7x5 Gy 4 3
5x6 Gy 4 3
10x4 Gy 1 1
initial steroid dose (prednisone equivalent) no steroids 41 27
daily dose <50 mg 38 25
daily dose 50–100 mg 38 25
daily dose >100 mg 26 17
unknown 8 5
extracranial tumor status primary tumor (PT) not detectable 54 36
PT detectable, not progressive 44 29
PT progressive 48 32
PT status unknown 5 3
any extracranial metastases 104 70
intracranial tumor status >3 metastases 83 56
  1-3 metastases 65 44
  number of metastases unknown 4 3
  largest metastasis >2 cm 53 35
  diameter of metastases unknown 17 12